- Brands
- Offerings
- Diagnostic Panels
- Knowledge Center
- Diagnostics
Core Laboratory
Core Laboratory
Webinars
Access on demand presentations led by subject matter experts and Abbott key opinion leaders to gain insight into industry trends, medical discoveries, healthcare technologies and much more.
Watch now. Visit us frequently for new content.
UTILIZING IMMUNe RESPONSE INSIGHTS IN
THE MANAGEMENT OF COVID-19
After two years of the COVID-19 pandemic, the scientific community has reached a better understanding of the pathogen (SARS-CoV-2), the routes and modalities of transmission, and the clinical course. However, as our assumptions about the COVID-19 disease have and will continue to evolve, how do we leverage testing tools to be better prepared ahead of a likely resurgence of the infection in the future?
Immune profiles and the role of testing algorithms in combating sars-cov-2
Speaker
Deborah L. Birx MD.
Former White House Coronavirus Coordinator, USA
Deborah L. Birx, MD., received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980 she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology.
Dr. Birx has spent her first career serving the United States, as an Army Colonel and later, running some of the most high-profile and influential programs at the U.S. Centers for Disease Control and Prevention and U.S. Department of State. Among her many achievements, she led one of the most influential HIV vaccine trials in history (known as RV 144 or the Thai trial), which provided the first supporting evidence of any vaccine’s potential effectiveness in preventing HIV infection. In 2014, Dr. Birx became an Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy.
More recently, Dr. Birx served as the White House Coronavirus Response Coordinator, where she made recommendations to the Vice President using complex data integration to drive decision-making, as well as worked closely with state officials across the country to provide state-specific advice and guidance.
Dr. Birx has spent her first career serving the United States, as an Army Colonel and later, running some of the most high-profile and influential programs at the U.S. Centers for Disease Control and Prevention and U.S. Department of State. Among her many achievements, she led one of the most influential HIV vaccine trials in history (known as RV 144 or the Thai trial), which provided the first supporting evidence of any vaccine’s potential effectiveness in preventing HIV infection. In 2014, Dr. Birx became an Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy.
More recently, Dr. Birx served as the White House Coronavirus Response Coordinator, where she made recommendations to the Vice President using complex data integration to drive decision-making, as well as worked closely with state officials across the country to provide state-specific advice and guidance.
LEARNING OBJECTIVES
This 3-part webinar series aims to provide a comprehensive update on:
- How to better use diagnostics and data to ensure patients thrive in the time of COVID?
- Who is at risk for severe COVID disease, hospitalization and deaths?
- What tools and strategies are needed to proactively protect the most vulnerable?
- What gaps remain?
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RELATED PAGES
sars-cov-2 epidemiological dynamics and serologic responses to variants
Speaker
Charles Y. Chiu MD. PhD.
University of California, San Francisco, USA
Charles Chiu, M.D./Ph.D. is Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory.
Chiu currently leads a translational research laboratory focused on next-generation sequencing assay development for infectious disease diagnostics and investigation of the pathogenesis of and immune responses to emerging pathogens, including Borrelia burgdorferi (Lyme disease), enterovirus D68 in acute flaccid myelitis, Zika virus, and, most recently, the SARS-CoV-2 coronavirus. He is also developing new technologies such as nanopore sequencing and RNA-Seq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of infections.
Chiu’s work has been supported by funding from the National Institutes of Health (NIH), US Center for Disease Control and Prevention (CDC), Biomedical Advanced Research and Development Authority (BARDA), Abbott Laboratories, Chan-Zuckerberg Biohub, the Steven and Alexandra Cohen Foundations, and the California Initiative to Advance Precision Medicine.Dr. Chiu has authored more than 200 peer-reviewed publications (over 30 related to COVID-19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Inc., Biomesense, and Poppy Health, Inc.
Chiu currently leads a translational research laboratory focused on next-generation sequencing assay development for infectious disease diagnostics and investigation of the pathogenesis of and immune responses to emerging pathogens, including Borrelia burgdorferi (Lyme disease), enterovirus D68 in acute flaccid myelitis, Zika virus, and, most recently, the SARS-CoV-2 coronavirus. He is also developing new technologies such as nanopore sequencing and RNA-Seq transcriptome profiling to develop predictive models using machine learning for host response based diagnosis of infections.
Chiu’s work has been supported by funding from the National Institutes of Health (NIH), US Center for Disease Control and Prevention (CDC), Biomedical Advanced Research and Development Authority (BARDA), Abbott Laboratories, Chan-Zuckerberg Biohub, the Steven and Alexandra Cohen Foundations, and the California Initiative to Advance Precision Medicine.Dr. Chiu has authored more than 200 peer-reviewed publications (over 30 related to COVID-19), holds over 15 patents and patent applications, and serves on the scientific advisory board for Mammoth Biosciences, Inc., Biomesense, and Poppy Health, Inc.
LEARNING OBJECTIVES
- SARS-COV-2 structure, origin, and transmission
- COVID-19 – clinical manifestations and treatment
- Symptomatology of long COVID
- Available diagnostic testing options
- Available testing options (design and uses)
- How are emerging SARS-CoV-2 variants discovered, monitored, and why are they concerning?
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RELATED PAGES
immunology and immune responses to sars-cov-2
Speaker
.jpg)
Daimon P. Simmons MD. PhD.
Brigham and Women’s Hospital, USA
Dr. Simmons is a practicing Clinical Pathologist with research interests in autoimmune disease and inflammation. His clinical activities incorporate both immunology and molecular biology. He is currently the Associate Medical Director for the Brigham and Women’s Hospital Clinical Immunology Laboratory. He also is an attending physician on the Molecular Pathology service. He has authored and co-authored multiple publications regarding diagnostic testing.
Dr. Simmons also teaches immunology, molecular pathology, and microbiology at Harvard Medical School. His research activities have led to the discovery of a macrophage super-activation state that has broad implications for inflammatory human disease, and his research program focuses on dissection of pathways to target macrophage super-activation.
Dr. Simmons also teaches immunology, molecular pathology, and microbiology at Harvard Medical School. His research activities have led to the discovery of a macrophage super-activation state that has broad implications for inflammatory human disease, and his research program focuses on dissection of pathways to target macrophage super-activation.
LEARNING OBJECTIVES
- The innate and adaptive immune system both play a role in protection against respiratory infection
- Adaptive immune responses are defined by clonal diversity and clonal expansion
- Sterilizing immunity is a difficult goal dependent on microbial neutralization
WHO SHOULD WATCH
- Laboratorians
- Clinicians
RELATED PAGES
Explore
Build key laboratory competencies and explore topics from various disciplines with our learning guides.
Find the latest information in laboratory science, therapeutic areas and Abbott innovation.
Watch the webinar to hear from experts how you can realize the value within and beyond your laboratory walls with a TVO approach.